{
    "nct_id": "NCT04565665",
    "official_title": "Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia",
    "inclusion_criteria": "1. Age greater than or equal 18 years.\n2. Participants with chest x-ray findings concerning for pneumonia from any cause, with clinical signs suggestive of at least moderate illness such as respiratory rate >20 breaths per minute or with oxygen saturation less than 93% on room air**\n3. Participants with COVID-19 associated pneumonia must meet baseline categorization of Moderate, Severe or Critical COVID-19 per FDA Guidance for Industry COVID-19: Developing Drugs and Biologics Products for Treatment or Prevention, February 2021.\n4. Negative pregnancy test in a woman with childbearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.\n5. Participant or legally authorized representative consent. Participants with diminished mental capacity may be allowed on to enroll on the study.\n6. Because of the nature of COVID-19, participants enrolled on this study with COVID-19 associated pneumonia may have been previously enrolled in other IND trials for their cancer diagnosis or for COVID-19. These enrollments will not exclude them from enrollment to this study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Moribund participants not expected to survive up to 48 hours\n* Participants with severe chronic liver disease (Childs-Pugh score > 10)\n* Pregnant and/or lactating women\n* Participants on extracorporeal membrane oxygenation",
    "miscellaneous_criteria": ""
}